Trials / Completed
CompletedNCT04710264
Aurora Test for Patients Treated With Recombinant Gonadotropins
An Observational Cohort Study to Evaluate the Expression Profiles of Oocyte-potency-related Genes in Ovarian Cumulus Cells From Patients Treated by Intracytoplasmic Sperm Injection (ICSI) That Are Treated With Recombinant Gonadotropins
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 137 (actual)
- Sponsor
- Fertiga, Belgium · Industry
- Sex
- Female
- Age
- 22 Years – 38 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational study. The main aim is to determine the expression of potential biomarker genes in the cumulus cells isolated from individual oocytes in two patient cohorts: recombinant human Follicle Stimulating Hormone(hFSH) and recombinant hFSH:human Luteinizing Hormone(r-hLH) ratio 2:1. Algorithms from gene combinations will be identified that predict embryo quality and pregnancy outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | AURORA-Rec | Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence. |
Timeline
- Start date
- 2021-02-15
- Primary completion
- 2023-12-31
- Completion
- 2025-09-01
- First posted
- 2021-01-14
- Last updated
- 2025-09-08
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04710264. Inclusion in this directory is not an endorsement.